Key result
Type 2 diabetes patients with CAD show ~2.8-fold higher serum CTRP4 levels than those without.
Why the study?
The study was conducted to evaluate the correlation between circulating C1q tumor necrosis factor-related protein 4 levels and coronary artery disease in patients with type 2 diabetes mellitus.
Are circulating CTRP4 levels associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus?
Observational (n=240)
No
Are circulating CTRP4 levels associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus?
Absolute Event Rate: 10.37% vs 3.75%
p-value: p=<0.01
Serum CTRP4 levels are significantly elevated in patients with type 2 diabetes and CAD, suggesting it may serve as a useful biomarker for predicting CAD occurrence and severity.
AIMS/INTRODUCTION: To evaluate the correlation of circulating C1q tumor necrosis factor-related protein 4 (CTRP4) with coronary artery disease (CAD) in type 2 diabetes mellitus patients. METHODS: A total of 240 individuals with type 2 diabetes mellitus were enrolled in our center between January 2020 and December 2020. They were assigned into two groups, including the CAD and non-CAD groups, based on coronary angiography or computed tomography angiography findings. Serum CTRP4 levels were detected by an enzyme-linked immunosorbent assay kit. The association of CTRP4 with CAD was determined by logistic regression analysis. The predictive value of CTRP4 for CAD was calculated by receiver operating characteristic curve analysis. RESULTS: Median serum CTRP4 amounts were markedly elevated in the CAD group in comparison with the non-CAD group (10.37 vs 3.75 ng/mL, P < 0.01). Binary logistic regression showed that CTRP4 was associated with CAD and even the amount of coronary artery lesions (P < 0.05). In receiver operating characteristic curve analysis, the area under the receiver operating characteristic curve was greater for CTRP4 compared with HbA1c or CRP (0.87 vs 0.74, 0.87 vs 0.80, P < 0.01). The area under the curve for CTRP4 and glycated hemoglobin in combination was larger than that obtained for CTRP4 combined with CRP (0.91 vs 0.87, P < 0.01). According to the maximum Youden index criteria, the optimal cut-off of CTRP4 was 5.42 ng/mL, which yielded a sensitivity of 84.4% and a specificity of 76.7% in predicting CAD in type 2 diabetes mellitus patients. CONCLUSIONS: Serum CTRP4 levels are positively correlated with CAD occurrence and severity. Combining CTRP4 and glycated hemoglobin has a better predictive value for CAD in type 2 diabetes mellitus patients.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2022) conducted an observational in Type 2 diabetes mellitus and coronary artery disease (n=240). Coronary artery disease (CAD) vs. Non-CAD was evaluated on Median serum CTRP4 levels (ng/mL) (p=<0.01). Median serum CTRP4 levels were significantly elevated in type 2 diabetes patients with coronary artery disease compared to those without (10.37 vs 3.75 ng/mL, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: